Results from a real-world data analysis show that Horizon Therapeutics’ Teppeza improves vision for patients with dysthyroid optic neuropathy (DON), a progressive eye disease related to thyroid dysfunction. Blindness is a leading fear of patients with the disease, making the therapy a promising prospect for many high-risk individuals.
According to Christine Klimanskis, ELS, “The analysis included patients with thyroid eye disease and dysthyroid optic neuropathy (DON) who were treated with Tepezza (teprotumumab-trbw, Horizon Therapeutics) between January 2020 and September 2022. After treatment, visual acuity, proptosis, diplopia and clinical activity score improved in eyes with DON. Many of the patients had not responded to previous treatments, according to the release.”
To read more, click here.
(Source: Healio News, March 14th, 2023)